Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring

      Cardiovascular medicine has become increasingly complex due to the often bewildering volume of information and the rapid diagnostic and treatment advancements achieved over the last several years. This evolution has led to increasing enthusiasm for quantitative risk scoring to guide clinical decision-making.
      • Fuster V.
      The proliferation of scoring systems.
      There are now >350 risk scores available to predict future clinical course and assist in management decisions in cardiology alone.
      • Fuster V.
      The proliferation of scoring systems.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fuster V.
        The proliferation of scoring systems.
        J Am Coll Cardiol. 2017; 69: 1640-1641
        • Maron M.S.
        • Rowin E.J.
        • Wessler B.S.
        • et al.
        Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy.
        JAMA Cardiol. 2019; 4: 644-657
        • Elliot P.M.
        • Anastasakis A.
        • Borger M.A.
        • et al.
        ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy.
        Eur Heart J. 2014; 35: 2733-2779
        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • et al.
        2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2011; 124: 2761-2796
        • Maron B.J.
        • Spirito P.
        • Shen W.-K.
        • et al.
        Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
        JAMA. 2007; 298: 405-412
        • Maron B.J.
        • Rowin E.J.
        • Casey S.A.
        • et al.
        Hypertrophic cardiomyopathy in children, adolescents and young adults associated with low cardiovascular mortality with contemporary management strategies.
        Circulation. 2016; 133: 62-73
        • Maron B.J.
        • Nishimura R.A.
        • Maron M.S.
        Shared decision-making in HCM.
        Nat Rev Cardiol. 2017; 14: 125-126
        • Brush Jr., J.E.
        • Krumholz H.M.
        Clinical decision making in cardiology.
        in: Zipes D.P. Libby P. Bonow R.O. Mann D.L. Tomaselli G.F. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 11th Edition. Elsevier, Philadelphia2018: 25-32
        • Wang J.
        • Zhang Z.
        • Yuancheng L.
        • et al.
        Variable and limited predictive value of the European Society of Cardiology hypertrophic cardiomyopathy sudden-death risk model: a meta-analysis.
        Can J Cardiol. 2019; 35: 1791-1799